Currently, retatrutide is in phase 3 trials that could be released by the end of 2025
So, what does this mean for people with depression and anxiety who are considering GLP-1 medications
However, as described earlier, its favourable effects on lipolysis and energy expenditure while reducing food intake make it an attractive option, especially if combined with the insulinotropic action of GLP-1
As of now, only one randomized clinical trial has been published that evaluated the effects of a GLP-1RA exenatide in patients with AUD 12
In short, you have more energy to exercise, and your body can burn fat stores more efficiently
Peptides have swept the nation as the latest wellness trend, dominating conversations on social media and at dinner parties across the country